Sequenom Inc

Sequenom — Investor Day (September 2015)

109 slides from Sequenom's investor day presentation, Sep 28, 2015

  1. Slide 1: Investor + Analyst Day

    INVESTOR + ANALYST DAY September 28, 2015

  2. Slide 2: Welcome

    Welcome Dirk van den Boom, PhD Interim President and CEO Chief Scientific & Strategy Officer

  3. Slide 3: Forward-looking statements

    Forward-looking statements Except for historical information, matters set forth in this presentation, including statements regarding Sequenom’s plans, potential, opportunities, financial or other expectations, projections, goals, objectives, milestones, strategies, market growth, timelines, product

  4. Slide 4: Today's agenda

    Today’s agenda Opening remarks Dirk van den Boom Corporate vision + overview Dirk van den Boom Reproductive health + genetic testing Mathias Ehrich, Rob Lozuk Coffee break Oncology Mathias Ehrich, Daniel Grosu Closing remarks Dirk van den Boom

  5. Slide 5: Speakers

    Speakers Mathias Ehrich, MD Rob Lozuk Daniel Grosu, MD Senior Vice President, Senior Vice President, Senior Vice President, Research and Development Commercial Operations Chief Medical Officer

  6. Slide 6: Corporate vision and overview

    Corporate vision and overview

  7. Slide 7: Sequenom: positioning for 2020

    Sequenom: positioning for 2020 Prenatal market is rapidly evolving creating both challenges and opportunities Recent performance does not reflect Sequenom’s potential Entire organization understands the challenges Sequenom is focused on driving value, leading innovation, and creating a sustainable b

  8. Slide 8: Performance to date

    Performance to date Launched three new laboratory-developed tests, VisibiliT™ in the United States, HerediT® UNIVERSAL To date results: and MaterniT GENOME™ Total Net earnings revenues of of $5.3 $70.6 million, million, including including $21 $ 4.0 million million gain in from license Illumina reve

  9. Slide 9: Providing unique insights into your health all starts with a simple blood draw…

    Providing unique insights into your health all starts with a simple blood draw…

  10. Slide 10: Our vision

    Our vision Interpreting the genome to improve your life

  11. Slide 11: Sequenom's distinction

    Sequenom’s distinction Innovator Committed to excellence. Responsible for new standard for noninvasive prenatal testing and the largest new global diagnostic category. Trusted Peer-reviewed publications and transparency in medical education, billing and commercialization. Comprehensive Most advanced

  12. Slide 12: Sequenom evolution

    Sequenom evolution Research to commercial [ 2014 ] NIPT innovator Focused operation NIPT licensing pools Discovery/clinical validation of Divested biosciences business Established global patent pool NIPT1 with Illumina for broad NIPT Launched MaterniT21 technology access laboratory-developed test (L

  13. Slide 13: Reproductive health

    Reproductive health High risk pregnancies MaterniT21® PLUS Market opportunity Invasive procedures Noninvasive prenatal test Annual births 97% of procedures have normal Laboratory-developed test 750K high-risk US births annually results (LDT) to identify pregnancies at 3.5M average risk US births Cos

  14. Slide 14: Trusted clinical partners

    Trusted clinical partners Sequenom performance “3 out of 4 maternal “MaterniT21 PLUS is “Clinicians ranked MaterniT21 fetal medicine recommended by PLUS higher than its competitors specialists use 84% of clinicians – in the 2 categories that matter MaterniT21 PLUS.” more than any other most to clini

  15. Slide 15: Multi-pronged business model

    Multi-pronged business model Embracing partnerships to enable adoption Doctors / Industry-leading, large-scale, next-generation sequencing patients / clinical laboratories labs • Serving 3,000+ doctors and 37 lab partners Processed over 500,000 genomic tests Sequenom / Licensing partnerships Illumin

  16. Slide 16: Operating in large markets

    Operating in large markets Addressable worldwide market opportunities by 2020 $14B $21B Oncology detection Sequenom Addressable Market $2B Oncology Carrier $2B profiling $3B NIPT Prenatal Other reproductive Oncology Oncology Addressable testing health profiling detection market

  17. Slide 17: Translating to results

    Translating to results Over $500M revenues by +$50M/yr NIPT test fees and royalties, with continued adoption of pooled patent globally and NIPT growth in international Oncology markets Patents extend beyond 2030 NIPT Liquid biopsy franchise in cancer profiling Royalty and detection Other 2020 revenu

  18. Slide 18: Growth drivers

    Growth drivers Products for growth Reproductive health Growing desire for complete karyotype level genomic health information Burgeoning demand for average risk screen for base chromosomal aneuploidies Broad international growth opportunities Liquid biopsy in oncology Therapy profiling / monitoring

  19. Slide 19: Key takeaways

    Key takeaways Innovation Trusted clinical Strong product Focused leader partner pipeline execution Provides innovative Products and practices Addresses major unmet Growing top-line solutions to the most trusted by physicians, needs and aims to revenue through a pressing and complex patients, and pay

  20. Slide 20: Reproductive health and genetic testing

    Reproductive health and genetic testing Mathias Ehrich, MD Senior Vice President Research and Development

  21. Slide 21: Reproductive health and genetic testing

    Reproductive health and genetic testing

  22. Slide 22: Care continuum

    Care continuum Reproductive health and genetic testing Pre-pregnancy “I want to become pregnant.” Pregnancy “I am pregnant.” “Provider of choice” Post-pregnancy “Is my baby healthy?

  23. Slide 23: Leaders in noninvasive prenatal testing

    Leaders in noninvasive prenatal testing Shaping the field First to show robust clinical validation with over 200 trisomy 21 samples First to create robust, high-throughput clinical laboratory using next generation sequencing First to market in noninvasive prenatal testing using cell-free DNA with br

  24. Slide 24: Leading in scientific breakthroughs

    Leading in scientific breakthroughs Sequenom accomplishments Breakthrough innovations Foundational technology for all current NIPT Cell-free fetal DNA in maternal blood Next-generation sequencing of circulating cell-free DNA (ccfDNA) allows for accurate identification of fetal chromosomal abnormalit

  25. Slide 25: Leading in innovation

    Leading in innovation Sequenom accomplishments R&D advances Pioneering biochemistry and bioinformatics solutions Detection of balanced translocations High accuracy at low no-call rates Industry leading low false positive rates for reporting of sub-chromosomal events Genome-wide analysis of deletions

  26. Slide 26: Leading through responsible innovation

    Leading through responsible innovation Foundational technology Breakthrough innovations Leading clinical validation Leading clinical performance

  27. Slide 27: Leading through responsible innovation

    Leading through responsible innovation

  28. Slide 28: Leading laboratory performance

    Leading laboratory performance Sequenom accomplishments Clinical performance Consistent Consistent high low no-result sensitivity rate and (?1.2%) high specificity Consistent fast turn-around time (5.2 calendar days) MaterniT21® MaterniT21® Relative Chr PLUSreportedcases as PLUS reported cases sensi

  29. Slide 29: Case study; discordant trisomy test results

    Case study; discordant trisomy 18 test results Clinical presentation: 27 weeks GA AMA and ultrasound findings NIPT result: positive for trisomy 18 Other testing: Amnio FISH: negative Amnio karyotype: 46, XY, add (18)(p11.3) Amnio aCGH: 12 Mb gain of 18q11.1-12.1

  30. Slide 30: Invasive diagnostic testing for aneuploidy should be available for all women

    “Invasive diagnostic testing for aneuploidy should be available for all women, regardless of maternal age.” Screening for fetal chromosomal abnormalities ACOG Practice Bulletin 88, December 2007 Number 77, January 2007 Invasive prenatal testing for aneuploidy Number 88, December 2007

  31. Slide 31: Key innovations

    Key innovations

  32. Slide 32: Contextualizing cytogenetic abnormalities

    Contextualizing cytogenetic abnormalities Trisomy Chromosome 21 Down Syndrome Sub-chromosomal abnormality 4p- Chromosome 4 Wolf Hirschhorn Syndrome ggc.usg.edu/wiki/Down_Syndrome 13

  33. Slide 33: Why genome-wide content matters

    Why genome-wide content matters Of 452,901 pregnancies in California… T21—50% Current NIPT T18—13% (T21/18/13 and SCA) misses > 20% T13—5.5% of total cytogenetic abnormalities Sex chromosome aneuploidy—10% Triploidy—2.6% Other trisomy + ~1/1000 fetuses Robertsonian—4.4% show a sub chromosomal Other

  34. Slide 34: Leading through responsible innovation

    Leading through responsible innovation

  35. Slide 35: Leading laboratory performance

    Leading laboratory performance Positive predictive value (PPV) matters to clinicians and patients Laboratories Sequenom™1 Illumina®2 (22q experience Natera™ only)2 Samples analyzed for microdeletions 175,393 14,353 21,948 Abnormal results reported 55 29 97 Confirmed true positives 40 5 12 Confirmed

  36. Slide 36: Unmet needs for broad genome-wide coverage

    Unmet needs for broad genome-wide coverage A key opinion leader’s perspective Ronald J. Wapner, MD Board-certified in Maternal-Fetal Medicine and Obstetrics and Gynecology New York-Presbyterian/Columbia

  37. Slide 37: Shifting paradigm

    Shifting paradigm Genome-wide detection of larger cytogenetic abnormalities (> 7Mb events) T21 risk Microdeletion risk 20 25 30 35 40 45 50 “A twenty year old woman’s risk of having one of those major chromosome abnormalities would be less than 1/1000; however their risk of having a microdeletion is

  38. Slide 38: Shifting paradigm

    Shifting paradigm Genome-wide detection of larger cytogenetic abnormalities (> 7Mb events) Identification of clinically relevant sub-chromosomal aberrations otherwise missed by NIPT Aids in assessment of potential pregnancy complications/ risk of adverse events Early recognition can change pre- and

  39. Slide 39: Genome-wide vs targeted analysis

    Genome-wide vs targeted analysis Genome-wide analysis Every chromosome analyzed Most comprehensive NIPT to date Allows for expanded clinical information without adding additional “targets” Targeted analysis Limited to only target regions of specific chromosome/ chromosome positions Higher failure ra

  40. Slide 40: Leading through responsible innovation

    Leading through responsible innovation

  41. Slide 41: Genome-wide content

    Genome-wide content oly = =— Matermnil = —___ ——— @ "s Gays

  42. Slide 42: Analyzed chromosomal regions

    Analyzed chromosomal regions Coverage for MaterniT™ GENOME vs. competitors MaterniT GENOME analyzes every chromosome and provides distinct results for: Any trisomy or monosomy Sex chromosome aneuploidy Existing select seven microdeletions Deletions or duplications ? 7Mb Unbalanced translocations ? 7

  43. Slide 43: Validating MaterniT GENOME

    Validating MaterniT™ GENOME in silico 01simulation Based on chromosomal events in the ClinGen Structural Variant Working Group database > 2.6 million cases simulated Model mixtures gDNA mixtures + “spike-in” cfDNA samples to validate performance > 960 gDNA mixtures used cfDNA samples Use of > 1000 e

  44. Slide 44: Validating MaterniT GENOME

    Validating MaterniT™ GENOME Clinical validation results Blinded case-control study with > 1000 plasma samples from pregnant women. Results confirm high sensitivity and specificity

  45. Slide 45: Why genome-wide content matters

    Why genome-wide content matters Of 452,901 pregnancies in California… Current NIPT (T21/18/13 and SCA) misses > 20% of total cytogenetic abnormalities 1. Norton, M. Cell free DNA analysis vs. sequential screening as primary testing considering all fetal chromosomal abnormalities. Presented at Societ

  46. Slide 46: Why genome-wide content matters

    Why genome-wide content matters Of 452,901 pregnancies in California… Genome wide NIPT covers 95% of cytogenetic abnormalities and select microdeletions 1. Norton, M. Cell free DNA analysis vs. sequential screening as primary testing considering all fetal chromosomal abnormalities. Presented at Soci

  47. Slide 47: Leading test portfolio

    Leading test portfolio Leveraging a proven and validated technology T21, T18, gender T21, T18, T13, Genome-wide testing SCA, ESS for CNVs > 7 Mb, Result reported as selected MDs risk score Result reported as positive, negative, Result reported as additional findings positive, negative The VisibiliT™

  48. Slide 48: Take-home messages

    Take-home messages Shaping the future of NIPT Best-in-class technology Robust product portfolio spanning high content needs and cost effective requirements Continuous and responsible innovation

  49. Slide 49: Reproductive health and genetic testing

    Reproductive health and genetic testing Rob Lozuk Senior Vice President Commercial Operations

  50. Slide 50: Commercial execution

    Commercial execution

  51. Slide 51: Size of opportunity

    Size of opportunity US increased risk and average risk births 3.5M births1 750K births1 US high risk US average births risk births 1. Martin JA, et al. Division of Vital Statistics. Births: Final data for 2013. National Vital Statistics Reports. 2013;62(9). 3 Online at http://www.cdc.gov/nchs/births

  52. Slide 52: Size of opportunity

    Size of opportunity Highlights of major regions offering NIPT 80M+ births2 1.5M NIPT Current Regions offering penetration NIPT $3+ billion total NIPT market opportunity worldwide1 1. 2. Morgan Stanley Research, NIPT Competition Evolves, December 2, 2014. Citi Research, Life Science Tools and Diagnos

  53. Slide 53: NIPT market drivers

    NIPT market drivers The traditional view of the market is changing HIGH RISK AVERAGE RISK Large; growth continues Emerging market segment Advanced maternal age original Physician and patient demand driver of prenatal testing for chromosomal abnormalities Global societies support Traditionally T21, T

  54. Slide 54: Market dynamics

    Market dynamics NIPT future evolution

  55. Slide 55: Positioned to serve the MFM + OB customer groups

    Positioned to serve the MFM + OB customer groups Growing our reproductive health franchise Large whole-genome Broad and differentiated sequencing footprint product portfolio Comprehensive Focused commercial customer solutions organization Trusted partner Enabling the global market

  56. Slide 56: Large whole-genome sequencing footprint

    Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market

  57. Slide 57: Large whole-genome sequencing footprint

    Large whole-genome sequencing footprint Sequenom Laboratories CAP-accredited First clinical Capacity to + CLIA-certified laboratory to accommodate molecular operationalize significant diagnostics and scale NGS growth laboratories

  58. Slide 58: Large whole-genome sequencing footprint

    Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market

  59. Slide 59: Our portfolio today

    Our portfolio today Comprehensive reproductive health franchise to service the MFM and OB communities Carrier HerediT screen ® UNIVE that d Genome-wide MaterniT™ GENOME fetal aneuploidies > 250 disorders HerediT Carrier screen ® CF that MaterniT21® PLUS Select fetal aneuploidies detects > 136 cystic

  60. Slide 60: Changing the game

    Changing the game Unmet needs Occurrence of sub-chromosomal abnormalities is independent of maternal age Societies show appreciation for information not seen in conventional screening More content Identifies >95% of chromosomal anomalies No other competitor comes close Differentiation Industry leadi

  61. Slide 61: Broad and differentiated product portfolio

    Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market

  62. Slide 62: Patient experience

    Patient experience Our focus is multi-faceted and a high priority in the business

  63. Slide 63: Comprehensive customer solutions

    Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market

  64. Slide 64: MFM commercial organization

    MFM commercial organization Historical approach to the market was successful 110+ f nnel Product portfolio Logistics Reproductive health tests NPS survey score 92 addressing MFM needs (-100 to +100 scale)1 Billing Customer service MaterniT21 MaterniT GENOME PLUS National Genetic counselors accounts

  65. Slide 65: Broad NIPT adoption via OB/GYN channel

    Broad NIPT adoption via OB/GYN channel

  66. Slide 66: Organization structured by customer segment

    Organization structured by customer segment MFM and OBGYN dedicated team Grow reach, frequency 110+ fi nel Product portfolio + utilization Scale Structured as market by call dictates point OBGYN Universal products carrier Simplify product mix Laser focus on screening + align to customer continued im

  67. Slide 67: Focused commercial organization

    Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market

  68. Slide 68: Breadth of coverage partners

    Breadth of coverage 37 partners 200M+ 44M Global partners US commercial lives US government-funded across 44 countries covered lives

  69. Slide 69: In-network strategy

    In-network strategy The value of an in-network provider Sequenom Stabilize Payers direct reimbursement care to in-network laboratories Allows for expansion as tests are offered Doctors Penalties Contractually and bound fee reductions to utilize with in-network use of out-of-network laboratories labs

  70. Slide 70: Enabling the global market

    Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market

  71. Slide 71: Enabling the global market

    Enabling the global market Leveraging patent pool agreement to enable NIPT globally Revenue realized with every test Substantial future value PATENT POOL CONTENT GLOBAL LICENSES The patent pool combines critical NIPT ? 32 organizations globally to data granted patents and patent applications license

  72. Slide 72: Potential annual license revenue

    Enabling the global market Potential annual license revenue Active partners Locations Annual licensing revenue 14 > 40 10 accts > 80 accts countries countries $6–10M $50M + Today Future Today Future Today Future

  73. Slide 73: Key takeaways

    Key takeaways Well positioned for future growth Unparalleled in-network footprint Expansive product portfolio and commercial focus that aligns to customer needs Commitment to the patient experience Numerous revenue streams that monetize the rapidly expanding global marketplace

  74. Slide 74: Oncology

    Oncology Mathias Ehrich, MD Senior Vice President Research and Development

  75. Slide 75: Experience and expertise in oncology

    Experience and expertise in oncology Sequenom milestones EpiTYPER® OncoCARTA™ UltraSEEK™ First in methylation First in mutation First in sensitivity Oncology expertise Sequenom oncology today Reproductive health experience MaterniT21® PLUS NIPT + cancer MaterniT™ GENOME First in NIPT First case Firs

  76. Slide 76: Incidental NIPT finding

    Incidental NIPT finding Patient presented at age High risk indication AMA Gestational age 10 weeks Normal genome profile May 2014 Profile Sept. 2014 Profile – after surgery differentiated adenocarcinoma, Stage II, 49 lymph nodes negative for metastasis

  77. Slide 77: Patient story

    Patient story Video Eunice Lee, M.D.

  78. Slide 78: Case examples

    Case examples Sequenom Laboratories 400,000 Data from Sequenom samples > 55% 18 of malignant malignant cases Laboratories previously unknown Altered Genomic alterations genomes prevent 40 “Non-reportable” cases samples, accurate NIPT reading patients and physicians decide follow-up

  79. Slide 79: Case examples

    Case examples Tumor types identified Uterine leiomyomas Solid tumors Hematological tumors 20 cases 9 cases 9 cases Benign smooth Breast, colon, Non-Hodgkin, Multiple muscle neoplasm angio-sarcoma, other myeloma, T-cell lymphoma, carcinoma CML, Hodgkin Key questions How do we have to Is this a lot of

  80. Slide 80: Laboratory benchmark

    Laboratory benchmark Cases of cancer detected in pregnant population 10 15 ~13 cases cases cases per per per 100,000 100,000 100,000 Lee, 2012 Eibye, 2013 Sequenom Australia Denmark R&D analysis* 1994—2008 1977—2006 2013—2015 *Note: R&D analysis based on research consented cohort of 78K

  81. Slide 81: Challenge of ctDNA

    Challenge of ctDNA 6000 600 6 copies copies copies cfDNA ctDNA Mutated ctDNA Only 6copies

  82. Slide 82: Sequenom technology solution

    Sequenom technology solution Proprietary biochemistry + bioinformatics = CodeBreaker™ 0.010 Raw data 0.008 0.010 0.006 CodeBreaker™ 0.004 0.008 0.002 0.010 Biochemistry 0.010 Bioinformatics 0.008 0.000 0.008 0.006 1293500 1294500 1295500 0.006 0.004 0.006 0.004 0.004 0.002 0.002 0.002 0.000 0.000 12

  83. Slide 83: How do we do it?

    How do we do it? EGFR T G Mutation Challenge The trick is not to find a needle in a haystack Detecting mutations is not difficult – they are readily visible The challenge is to differentiate sequencing errors from true mutations CodeBreaker™ Codebreaker organizes the sequence reads according to thei

  84. Slide 84: Our product

    Our product OncoPlasma™ – ctDNA detection + profiling assay for pan-cancer Metric OncoPlasma Total number of genes 134 measured OncoPlasma™ is designed for cancer patients afflicted with late stage (Stage Target limit of detection 0.1-1% III-Stage IV), non-hematological malignancies Target specifici

  85. Slide 85: Genes in FDA / NCCN guidelines

    Genes in FDA / NCCN guidelines Clinical relevance of gene targets Panel composition by genes Genes Indications ALK NSCLC FDA / BRAF NSCLC, melanoma NCCN BRCA1* Ovarian cancer 8% EGFR NSCLC Other ERBB2 Breast, gastric cancer cancer pathway KIT Melanoma genes 52% Clinical trials KRAS Colorectal cancer

  86. Slide 86: OncoPLASMA in action

    OncoPLASMA™ in action The power of Sequenom We asked a simple question: Can we find mutations in the cancer cases we have seen in the lab? We used the same library that was used for NIPT and ran it with OncoPLASMA.

  87. Slide 87: OncoPLASMA in action

    OncoPLASMA™ in action The power of Sequenom We found a TP53 mutation at 2.7% in this plasma 30k 900 seq mutated reads reads TP53 A99V This demonstrates the power of combining expertise in copy number and mutation analysis “P53” by Thomas Splettstoesser -Based on atomic coordinates of PDB 1TUP, rende

  88. Slide 88: Colon cancer case study

    Colon cancer case study Colon cancer stage IV (T3N1M1) BRAF V600E BRAF V600E mutation indicating sensitivity for proteasome inhibitors (Vemurafenib) Mutation frequency in: Tumor: 15% Tumor tissue Plasma DNA: 13% BRAF V600E Plasma Tumor profiling

  89. Slide 89: Colon cancer case study

    Colon cancer case study Colon cancer stage IV (T3N1M1) Plasma shows the tumor CNVs as well as the tumor mutations Copy number variations indicate that ~20% of the tumor is genetically abnormal Tumor genetics likely heterogeneous (chr6del) BRAF V600E mutation indicating sensitivity for proteasome inh

  90. Slide 90: Market opportunity for early detection cancer

    Market opportunity for early detection cancer Copy number variations and mutations are important CNVs Mutation Copy number analysis is unique to Sequenom

  91. Slide 91: Market opportunity for early detection cancer

    Market opportunity for early detection cancer The addition of DNA methylation analysis can provide superior results CNVs Mutation Sequenom has world-leading expertise in DNA methylation analysis: Tech + application development Methylation Functional research in developmental biology Fetal fraction p

  92. Slide 92: Market opportunity for early detection cancer

    Market opportunity for early detection cancer These programs can potentially be targeted towards CNVs Mutation • General population screening for colon cancer Follow-up testing for node positive CT scan in lung cancer screening Methylation Or general cancer recurrence monitoring

  93. Slide 93: Another cancer case study

    Another cancer case study What plasma can do in early detection One more exciting example Tumor shows numerous copy number variations Plasma confirms presence of low levels of tumor DNA Tumor tissue • Lung cancer stage 1a Plasma

  94. Slide 94: Oncology

    Oncology Daniel Grosu, MD Senior Vice President, Chief Medical Officer

  95. Slide 95: Sequenom liquid biopsy collaboration

    Sequenom liquid biopsy collaboration A key opinion leader’s perspective Eric Topol, M.D. Chief Academic Officer, Scripps Health Director, Scripps Translational Science Institute

  96. Slide 96: Diversity of cancer

    Diversity of cancer One name… many diseases Glioblastoma Lung adenocarcinoma Breast 200+ types of cancer Melanoma Colorectal Ovarian Uterine

  97. Slide 97: Cancer touches nearly everyone

    Cancer touches nearly everyone Huge societal and personal impact > 1.7 million 14.5 million 1 in 3 1 in 2 New cancer cases in People living with Americans will be Americans diagnosed the US annually cancer in the US diagnosed with cancer with cancer die from it American Cancer Society American Cance

  98. Slide 98: Cancer is a very complex disease of the genome

    Cancer is a very complex disease of the genome Tumor accessibility and heterogeneity—mitigated by liquid biopsy Lung metastases S1 S3 Chest-wall metastases S2 Primary tumor 10 cm Perinephric metastases LEGEND S Tissue Sample Identifier

  99. Slide 99: Clinical utility of ctDNA along the patient journey

    Clinical utility of ctDNA along the patient journey Detection & Profiling SIGNS & SYMPTOMS ADJUVANT TREATMENT NEO-ADJUVANT TREATMENT MORE TREATMENT DIAGNOSIS RECURRENCE SUB-CLINICAL DISEASE CURATIVE-INTENT SURGERY DETECTION: Presence & Burden of Disease PROFILING: Presence of Actionable Targets Scre

  100. Slide 100: Clinical utility: detection

    Clinical utility: detection Colorectal cancer screening example SIGNS & NEO-ADJUVANT ADJUVANT MORE SYMPTOMS TREATMENT TREATMENT TREATMENT SUB-CLINICAL DIAGNOSIS CURATIVE-INTENT RECURRENCE DISEASE SURGERY CLINICAL CONTEXT >130,000 new CRC cases per year in the US > 50% CRC cases diagnosed at later st

  101. Slide 101: Clinical utility: detection

    Clinical utility: detection Lung cancer screening example Stage at diagnosis Five-year relative survival rate Lung cancer Lung cancer 4% 15% 22% 56% 52% 24% LOCAL REGIONAL DISTANT LOCAL REGIONAL DISTANT Current lung cancer screening paradigm: computed tomography (CT) ~25% “suspicious findings”—to be

  102. Slide 102: Clinical utility: profiling

    Clinical utility: profiling Targeted treatment selection example Effectiveness of drugs by disease category Response (panitumumab) to EGFR blockade ANTIDEPRESSANTS 62% Mutant KRAS ASTHMA DRUGS 60% DIABETES DRUGS 57% ARTHRITIS DRUGS 50% Wild-type KRAS ALZHEIMER’S DRUGS 30% CANCER DRUGS 25% PR: partia

  103. Slide 103: Clinical foundation

    Clinical foundation Developing the clinical evidence base Translational research Clinical validation Colon cancer Profiling Lung cancer Detection Breast cancer Melanoma KOL SQNM Other studies Clinical studies Clinical Advisory Build clinical experience Board evidence for w/ leading future LDT cancer

  104. Slide 104: Upcoming liquid biopsy RUO test

    Upcoming liquid biopsy RUO test Pan-cancer profiling for actionable genomic alterations OncoPlasma family of Sequenom ™ is poised ctDNA to tests be the first of a Aimed at molecular profiling of later-stage solid tumors where biopsy is not feasible or cannot provide sufficient material for NGS panel

  105. Slide 105: Product pipeline

    Product pipeline Profiling and detection Oncology Research and product lines development Validation Commercial Cancer profiling $2B+ Multi-marker pan-cancer Market Opportunity translational applications by 2020 Cancer detection $14B+ Multi-marker pan-cancer Market detection panel for clinical Opport

  106. Slide 106: Key takeaways

    Key takeaways The Sequenom advantage Advanced biochemistry + bioinformatics Built upon extensive clinical expertise in oncology and NIPT Test for all classes of genomic alterations in cancer Point mutations Insertions + deletions Methylation Translocations Copy number variants Fragment size Clinical

  107. Slide 107: Wrap-up

    Wrap-up Dirk van den Boom, PhD Interim President and CEO Chief Scientific & Strategy Officer

  108. Slide 108: Positioning for Growth

    Positioning for Growth Positioned to capitalize on Average Risk market MaterniT™ GENOME paves the way for comprehensive information Opportunity for proprietary and potentially “kitable” assays in Oncology Significant opportunity in oncology through circulating tumor DNA detection and profiling New o

  109. Slide 109: Dirk van den Boom, PhD Carolyn Beaver

    Dirk van den Boom, PhD Carolyn Beaver Interim President and CEO Senior Vice President, Chief Scientific & Strategy Officer Chief Financial Officer Mathias Ehrich, MD Rob Lozuk Daniel Grosu, MD Senior Vice President, Senior Vice President, Senior Vice President, Research and Development Commercial Op

Sequenom — Investor Day (September 2015) on 6ix